{"name":"Mycovia Pharmaceuticals Inc.","slug":"mycovia-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Oteseconazole (VT-1161)","genericName":"Oteseconazole (VT-1161)","slug":"oteseconazole-vt-1161","indication":"Vulvovaginal candidiasis","status":"phase_3"}]}],"pipeline":[{"name":"Oteseconazole (VT-1161)","genericName":"Oteseconazole (VT-1161)","slug":"oteseconazole-vt-1161","phase":"phase_3","mechanism":"Oteseconazole is a selective inhibitor of fungal lanosterol 14α-demethylase (CYP51) that disrupts ergosterol synthesis in fungal cell membranes.","indications":["Vulvovaginal candidiasis","Oral candidiasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-04-02","type":"deal","source":"PR Newswire","summary":"Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Recognition for the Inclusion of VIVJOA® (Oteseconazole) Capsules in the Chinese National Reimbursement Drug","headline":"Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Recognition for the Inclusio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBIelZoTEd1MmNHME1RRVMwUXNaRGk0YkNIbWJtSDY2SERxWEhHZHpSdTBHUDVEOHg2QmplbjI2LWxMZmFCUlVJcDQ3bUhpTU1sR2JGeDNDR3BaaHY5ZlpFemIyWldUdk5vMlZKdHUyRHRUSHY4OVJJbQ?oc=5","date":"2024-07-01","type":"pipeline","source":"The Pharma Letter","summary":"Mycovia Pharmaceuticals - The Pharma Letter","headline":"Mycovia Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE9oejVDN3pnd2dyOFFjamxSZWdibEJZM2szb2U1QkdtVXVKYnNPVUJ2OFpMaG5JNElfOEVQMlVLZWRQTGVnUTFSV0ZzcDc1MWJwZWZZcUNGWlRmYVBVQVRGNjVlRl9Udw?oc=5","date":"2024-03-26","type":"pipeline","source":"Anton Health","summary":"Limited Distribution Updates - Anton Health","headline":"Limited Distribution Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNT3FyY3RLbllQVlJVU1czVnY0LV96QjltZ1dMdW9sTkNsaHNnWDQ1S1dzQkdoY1VxT3YxcUlDNzhucmtJdnoyU1BTX1NsZjZOV2JsREo1MlJnZmVleE5QN21rREVYUWNBZkpoMUxYREJESGhXV0RUOThEUHRJOG9EZDBCcF96V2lJcHRpek5ldk03dERtemNlU3A4eTZteTEwN2lDcW5Delhxd0Z5RHNHZTkzT2NMcXFwM0NycGNYWUYtSjNMc2p3TVo1MVdaUQ?oc=5","date":"2024-03-19","type":"pipeline","source":"Pharmacy Times","summary":"AllianceRx Walgreens Pharmacy to Exclusively Provide Vivjoa for Recurrent Vulvovaginal Candidiasis - Pharmacy Times","headline":"AllianceRx Walgreens Pharmacy to Exclusively Provide Vivjoa for Recurrent Vulvovaginal Candidiasis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8yY3k2MVgtc0s0ME9xeWFpYXNkTG56US0tTWF4WlM5WXVEbzkyTlVrUWRfNHBxX2V2cGg4Ymxmb0RiTFZQYlZZSG5aUDlOWFZSdHd3OFJGZFJTSzRGWUZFMkFsdlQ2MGhINkJLcVl2dzFBNFRJQldNRXE5QTh6czQ?oc=5","date":"2023-01-31","type":"pipeline","source":"Pharmacy Times","summary":"Vivjoa From Mycovia Pharmaceuticals, Inc - Pharmacy Times","headline":"Vivjoa From Mycovia Pharmaceuticals, Inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQNl9xS09abnJVTVludzBHbTl6SktpQzR2R3BFdFdCUTVPeHhKcTEwTDBBdlpoUTI4ZlZ3by1DeVEtRWlyUHNKNkpqcDAzV3Yxd1VwNDh0TzBjWGJCWVNndHB2QS1aNDc3SkFsMWN4NjUzT1lDUkJEaC0xV2x6VGthVF96R1lORmFHeEg4VFNPWWExZThzNEMzMUd2YTZzaDd0dHc?oc=5","date":"2022-09-14","type":"pipeline","source":"Grand View Research","summary":"Vulvovaginal Candidiasis Treatment Market Size Report, 2030 - Grand View Research","headline":"Vulvovaginal Candidiasis Treatment Market Size Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQRDIyZ3l0bUZCTXJvWl9icnZBS1lEVE50Rno3MmZUZHFHbkJSTFZLTGtfTlUwekhhTXRjVDN2aUsxenIzUm8zZ3JDWUpsaFVZYzA0SGVZdVppcHlrTlZIbGhVMERmR2FJeHA0UWwxbkRIUWhqOFljYmlvVWhJeFdYNGdkZ2Nack91MlRCMUFNTVBXejVPX1E?oc=5","date":"2022-08-04","type":"trial","source":"Clinical Trials Arena","summary":"VIVJOA (oteseconazole) to Treat Recurrent Vulvovaginal Candidiasis, USA - Clinical Trials Arena","headline":"VIVJOA (oteseconazole) to Treat Recurrent Vulvovaginal Candidiasis, USA","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}